Clinical trials: Steatohepatitis, Nonalcoholic
PreDiabetes, Insulin Resistance
Disease Prevention in Clinical Practice Base on Patient Specific Physiology
It is well known that the Type 2 diabetes and vascular disease are preceded by over ten years by metabolic dysfunction and anatomic changes that can be quantified.
- Conditions
- PreDiabetes, Insulin Resistance, Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis
- Trial name
- STOPDISEASE (NCT03308773)
- Testing
- Lifestyle modification in routine care of patients
- Volunteers
- 5,000 people
- Sponsor
- Pacific Coast Family Medical Group
Nonalcoholic Steatohepatitis
Dapagliflozin Efficacy and Action in NASH
This is a multicentre, randomized, placebo-controlled trial to assess the efficacy and safety of dapagliflozin on improving non-alcoholic steatohepatitis as determined by liver biopsies and metabolic risk factors.
- Trial name
- DEAN (NCT03723252)
- Testing
- Dapagliflozin
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nonalcoholic Steatohepatitis (NASH)
A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)
A Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH)
- Trial name
- NCT04616014
- Testing
- ORMD-0801 QD
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Oramed, Ltd.
NASH - Nonalcoholic Steatohepatitis
Study to Evaluate MET642 in Patients With NASH
A randomized, double-blind, placebo-controlled study to evaluate MET642 in NASH patients.
- Trial name
- NCT04773964
- Testing
- MET642
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- Metacrine, Inc.
NASH - Nonalcoholic Steatohepatitis, Bariatric Surgery Candidate
Gut Permeability and Bariatric-metabolic Surgery
Increased intestinal permeability and dysbiosis have been causally associated with NAFLD and NASH progression. However, to date, there are no systematic studies, on the effect of bariatric-metabolic surgery on intestinal…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Bariatric Surgery Candidate, Intestinal Permeability
- Trial name
- NCT05257200
- Where
- Austria
- Volunteers
- 125 people
- Sponsor
- Medical University of Vienna
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Metabolic Pathology of Pediatric NAFLD
Nonalcoholic fatty liver disease (NAFLD) is now the most common liver disease worldwide and affects nearly 40% of obese youth and up to 10% of the general pediatric population.
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
- Trial name
- NCT05430178
- Testing
- Oral sugar tolerance test, De novo lipogenesis test, Gluconeogenesis test
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
NASH - Nonalcoholic Steatohepatitis
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
This is a Phase 2a, randomized, parallel-group, placebo-controlled, double-blind, repeated-dose study to evaluate the safety and efficacy of three oral dose levels of HU6 compared to placebo over the course of 61 days in subjects…
- Trial name
- NCT04874233
- Testing
- HU6
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Rivus Pharmaceuticals, Inc.
Nonalcoholic Steatohepatitis
Norursodeoxycholic Acid vs. Placebo in NASH
This is a double-blind, randomised, multi-centre, placebo-controlled, comparative, phase IIb trial. The trial will be conducted with three treatment groups in the form of a parallel group comparison and will serve to compare oral…
- Trial name
- NCT05083390
- Testing
- norUrsodeoxycholic acid
- Where
- Austria
- Volunteers
- 363 people
- Sponsor
- Dr. Falk Pharma GmbH
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver Disease - Intermittent Calorie Restriction (FLICR) Study
Several diets have been proposed to reduce liver steatosis in patients with nonalcoholic fatty liver disease (NAFLD), and various effects on liver steatosis have been observed.
- Trial name
- NCT05309642
- Testing
- Intermittent calorie restriction, Standard of care
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Nonalcoholic Steatohepatitis, Type 2 Diabetes
Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D)
The study is stratified cluster randomized trial. The study population will include adults with T2D and presumed NASH.
- Trial name
- NCT05029583
- Testing
- routine screening, physician-driven screening
- Where
- Canada
- Volunteers
- 5,000 people
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis
Effects of Wheat-based diet vs. ATI-free diet on NASH
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2, Hyperlipidemias
- Trial name
- NASH-ATI (NCT04066400)
- Testing
- Nutritional Intervention
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Johannes Gutenberg University Mainz
Nonalcoholic Steatohepatitis (NASH)
The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis
This is a Phase 2, randomized, double-blind, placebo controlled, three arm study in adult men with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of LPCN 1144 in adult men with NASH.
- Trial name
- NASH (NCT04134091)
- Testing
- LPCN 1144 Formulation A, LPCN 1144 Formulation B
- Where
- 19 sites in United States
- Volunteers
- 56 people
- Sponsor
- Lipocine Inc.
Nonalcoholic Steatohepatitis (NASH)
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of CS0159 in subjects with Non-Alcoholic Steatohepatitis (NASH)
- Trial name
- NCT05591079
- Testing
- CS0159 (Linafexor)
- Where
- 17 sites in United States
- Volunteers
- 99 people
- Sponsor
- Cascade Pharmaceuticals, Inc
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD.
- Trial name
- NCT04944992
- Testing
- Efinopegdutide 20 mg/mL, Semaglutide 1.34 mg/mL
- Where
- 69 sites in United States, Argentina and 14 more
- Volunteers
- 145 people
- Sponsor
- Merck Sharp & Dohme LLC
Alcoholic Liver Disease, Non-Alcoholic Fatty Liver Disease
Integrated Approaches for Identifying Molecular Targets in Liver Disease
To provide a framework for successful clinical trials testing novel targets for therapy in liver disease. To identify molecular and cellular drivers of liver disease to provide a molecular classification and study the…
- Conditions
- Alcoholic Liver Disease, Non-Alcoholic Fatty Liver Disease, Steatohepatitis, Nonalcoholic, Steatohepatitis
- Trial name
- InLi (NCT03915002)
- Where
- United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
NASH - Nonalcoholic Steatohepatitis
Interest in "Combo" (a Combination of Dietary Supplements Including Probiotics) in NASH Improvement
The aim of this bicentre, prospective, placebo-controlled, double-blind, randomized, interventional study is to assess for the first time the effects of a Combo with probiotics and dietary supplements compared to placebo for…
- Trial name
- ICAN (NCT04781933)
- Testing
- Treatment with Combo
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Mativa-Tech SA
Patients With Nonalcoholic Steatohepatitis
Evaluate the Efficacy, Safety and Tolerability of Fecal Microbiota Transfer for the Treatment of Patients With Nonalcoholic Steatohepatitis
The EMOTION study is a multicentric, double-blind, controlled, parallel-group, phase IIa randomized Clinical trial to evaluate the efficacy, safety and tolerability of TMF capsules for the treatment of patients with NASH.
- Trial name
- EMOTION (NCT05622526)
- Testing
- Group 1 or Experimental group, Group 2 or Control group
- Volunteers
- 96 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.
- Trial name
- REVERSE (NCT03439254)
- Testing
- Obeticholic acid (10 mg), Obeticholic acid (10 mg to 25 mg)
- Where
- 192 sites in United States, Australia and 10 more
- Volunteers
- 919 people
- Sponsor
- Intercept Pharmaceuticals
HIV, Fatty Liver
Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients
People infected with HIV are living longer thanks to the use of antiretroviral therapy (cART). In aging HIV persons, other factors are associated with early death.
- Conditions
- HIV, Fatty Liver, Nonalcoholic Steatohepatitis
- Trial name
- NCT02210715
- Testing
- Isentress., Continue usual antiretroviral therapy
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying…
- Conditions
- Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
- Trial name
- NCT04643795
- Testing
- MGL-3196
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.